Skip to content

Neurobiological Mechanisms of High-Definition Transcranial Direct Current Stimulation (HD-tDCS) in Modulating Cortical Neuroplasticity to Improve Cognitive Function in Schizophrenia

Neurobiological Mechanisms of High-Definition Transcranial Direct Current Stimulation (HD-tDCS) in Modulating Cortical Neuroplasticity to Improve Cognitive Function in Schizophrenia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107788
Enrollment
Unknown
Registered
2025-08-18
Start date
2025-08-18
Completion date
Unknown
Last updated
2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

HD-tDCS Treatment Group:High-Definition Transcranial Direct Current Stimulation (HD-tDCS)
Healthy control group:None
Sham Stimulation Group:Sham High-Definition Transcranial Direct Current Stimulation (Sham HD-tDCS)

Sponsors

Affiliated Kangning Hospital of Ningbo University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Patient group:Meet the diagnostic criteria for schizophrenia according to the *Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5); 2.Patient group:Aged 18-60 years, regardless of gender; 3.Patient group:PANSS score >= 60; 4.Patient group:Consent to combined treatment with high-definition transcranial direct current stimulation (HD-tDCS); 5.Patient group:Willing to participate in the study and sign the informed consent form; 6.Healthy control group:Aged 18-60 years, regardless of gender; 7.Healthy control group:Willing to participate in the study and sign the informed consent form; 8.Healthy control group:No history of mental illness, not taking any psychiatric medications; 9.Healthy control group:No history of neurological diseases including epilepsy, brain trauma, stroke, or neurodegenerative conditions; 10.Healthy control group:No severe cardiovascular, endocrine, immune system, or other somatic disorders that may affect cognitive function; 11.Healthy control group:Based on the Wechsler Adult Intelligence Scale (WAIS) assessment, the IQ score was >= 90, indicating no cognitive dysfunction;

Exclusion criteria

Exclusion criteria: 1.Patient group:Severe agitation/impulsivity and self-harm/suicidal tendencies; 2.Patient group:Contraindications to treatment (e.g., intracranial metal implants); 3.Patient group:History of electroconvulsive therapy within the past month; 4.Patient group:Pregnancy; 5.Patient group:History of alcohol or other psychoactive substance abuse; severe physical illness; 6.Patient group:Intellectual impairment (IQ < 90); 7.Healthy control group:Family history of mental disorders (in first-degree relatives); 8.Healthy control group:Presence of severe sleep disorders, hearing or visual impairments that may affect cognitive test results; 9.Healthy control group:History of electroconvulsive therapy within the past month; 10.Healthy control group:Pregnancy; 11.Healthy control group:History of alcohol or other psychoactive substance abuse; severe physical illness; 12.Healthy control group:Intellectual impairment (IQ < 90);

Design outcomes

Primary

MeasureTime frame
RBANS;PANSS;

Secondary

MeasureTime frame
TMS-EEG cortical reactivity (TEP amplitude);PSP;

Countries

China

Contacts

Public ContactChen Zan

Affiliated Kangning Hospital of Ningbo University

751072412@qq.com+86 574 26302602

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026